Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Merck KGaA

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.

Merck KGaA

AZ gets first OK for PD-L1 inhibitor durvalumab

AZ gets first OK for PD-L1 inhibitor durvalumab the class already on the market from Bristol-Myers Squibb, Merck &Co, Roche and Merck KGaA/Pfizer, after the FDA placed durvalumab on a temporary clinical hold last year. ... Meanwhile Merck's Keytruda (pembrolizumab) has been filed for approval in

Takeda's gamble on Ariad pays off with Alunbrig approval

Takeda's gamble on Ariad pays off with Alunbrig approval Sales of Zykadia and Alecensa were $91m and $182m respectively last year, while Pfizer reported sales of $561m for Xalkori, which is co-promoted by Merck KGaA in the US.

Fresenius Kabi buys Akorn and Merck's biosimilar businesses

Fresenius Kabi buys Akorn and Merck's biosimilar businesses Fresenius Kabi has beefed up its pharmaceuticals division with deals to acquire US generic drugmaker Akorn for $4.3bn and Merck KGaA's fledgling biosimilars business for up to 670m ($730m). ... Adding in Merck's biosimilars business takes it right back

Roche claims another FDA green light for Tecentriq

Roche claims another FDA green light for Tecentriq Bristol-Myers Squibb and Merck &Co, which both reached the market ahead of Roche's drug for other cancer indications. ... The reality is that in time the three drugs - along with newer entrants such as Merck KGaA and Pfizer's Bavencio (avelumab) - will

Deal Watch March 2017

Deal Watch March 2017 Merck KGaA has partnered its product M1095 (ALX-0761), for plaque psoriasis, to Avillion.

[ Previous 5 results ] 17 18 19 20 21 22 23 24 25 26 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...